These updates emphasize the use of glucagon-like-peptide 1 (GLP-1) receptor agonists or sodium–glucose cotransporter 2 (SGLT2) inhibitors to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression. Here, GCG is linked to chronic kidney disease.